A Phase 2 Study of Ibrutinib Maintenance After Reduced-Intensity Conditioning and Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia
Phase of Trial: Phase II
Latest Information Update: 11 Nov 2019
Price : $35 *
At a glance
- Drugs Ibrutinib (Primary) ; Methotrexate; Sirolimus; Tacrolimus; Tacrolimus
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Chronic myeloid leukaemia; Graft-versus-host disease; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Therapeutic Use
- 04 Nov 2019 Planned End Date changed from 1 Mar 2020 to 1 Jan 2023.
- 04 Nov 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Jan 2022.
- 10 Oct 2017 Status changed from not yet recruiting to recruiting.